The Systemic Immune Markers at Diagnosis Can Predict the Survival Benefit in Advanced Breast Cancer

2021 ◽  
Vol 1 (5) ◽  
pp. 471-478
Author(s):  
SHOGO NAKAMOTO ◽  
MASAHIKO IKEDA ◽  
SHINICHIRO KUBO ◽  
MARI YAMAMOTO ◽  
TETSUMASA YAMASHITA ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Prognostic Markers ◽  
Absolute Lymphocyte Count ◽  
Advanced Breast ◽  
City Hospital ◽  
Immune Markers ◽  
First Line ◽  
Lymphocyte To Monocyte Ratio ◽  
Time To Treatment Failure

Background/Aim: It has been difficult to establish prognostic markers for overall survival (OS) in patients with advanced breast cancer (ABC). Although systemic immune markers were reported as prognostic markers in several cancers, their utility in ABC remains unclear. Patients and Methods: We retrospectively analyzed 331 ABC patients, who received treatment at Fukuyama City Hospital between April 2009 and December 2020. Results: Patients with high absolute lymphocyte count (ALC), low neutrophil-to-lymphocyte ratio (NLR), and high lymphocyte-to-monocyte ratio (LMR) had significantly longer OS (p=0.025, p=0.010, and p<0.001, respectively). High ALC and high LMR were independently associated with longer OS (p=0.020 and p=0.015, respectively). High ALC was also independently associated with longer time to treatment failure (p=0.014). Conclusion: These systemic immune markers at diagnosis can predict not only a better OS but also a better TTF after first-line treatment.

scholarly journals Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Shogo Nakamoto ◽  
Masahiko Ikeda ◽  
Shinichiro Kubo ◽  
Mari Yamamoto ◽  
Tetsumasa Yamashita ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Multivariable Analysis ◽  
Absolute Lymphocyte Count ◽  
Predictive Markers ◽  
Advanced Breast ◽  
Chemotherapeutic Regimen ◽  
Systemic Immunity ◽  
Lymphocyte Ratio ◽  
Lymphocyte To Monocyte Ratio

AbstractAlthough paclitaxel plus bevacizumab (PB) therapy is an effective chemotherapeutic regimen for HER2-negative advanced breast cancer (ABC), predictive markers for its effectiveness remain undefined. We investigated the usefulness of systemic immunity markers associated with lymphocytes as predictive markers for PB therapy in patients with HER2-negative ABC. We retrospectively reviewed data from 114 patients with HER2-negative ABC who underwent PB therapy from November 2011 to December 2019. We calculated the absolute lymphocyte count (ALC), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) as representative systemic immunity markers. The time to treatment failure (TTF) and overall survival (OS) of the patients with high ALC, low NLR, and high LMR were significantly longer compared with those of the patients with low ALC, high NLR, and low LMR. A multivariable analysis revealed that high ALC, low NLR, and low PLR were independent predictors for TTF and high ALC, low NLR, and high LMR were independent predictors for OS. Systemic immunity markers were significantly associated with longer TTF and OS in patients who underwent PB therapy and may represent predictive markers for PB therapy in patients with HER2-negative ABC.

scholarly journals Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Shogo Nakamoto ◽  
Junichiro Watanabe ◽  
Shoichiro Ohtani ◽  
Satoshi Morita ◽  
Masahiko Ikeda
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Advanced Breast Cancer ◽  
Independent Risk Factor ◽  
Multivariate Analyses ◽  
Optimal Choice ◽  
Advanced Breast ◽  
First Line ◽  
Time To Treatment Failure ◽  
Line Chemotherapy

AbstractPost-progression survival affects overall survival (OS) in patients with HER2-negative advanced breast cancer (HER2-ABC); thus, the optimal choice of first-line chemotherapy (1LCT) remains controversial. We investigated patients with HER2-ABC focusing on their sensitivity to 1LCT. We retrospectively analyzed patients with HER2-ABC who received 1LCT between January 2011 and December 2016 in three participating institutions. We identified 149 patients in the shorter and 152 patients in the longer time to treatment failure (TTF) groups. The median OS was significantly longer in the longer TTF group (hazard ratio [HR] 0.44, P < 0.001, log-rank). In the shorter TTF group, OS of patients who received paclitaxel plus bevacizumab (PB) therapy was significantly inferior to that of those who received chemotherapy other than PB (HR 2.57, P < 0.001, log-rank), and subsequent eribulin therapy significantly improved OS from 1LCT initiation (Wilcoxon P < 0.001); multivariate analyses showed that 1LCT PB therapy was an independent risk factor for poorer OS (HR 2.05, P = 0.003), while subsequent eribulin therapy was an independent prognostic factor for better OS (HR 0.56, P = 0.004). OS was significantly poorer in patients with HER2-ABC with a shorter duration of 1LCT, including PB therapy, while subsequent eribulin therapy improved OS.

346 Taxol or doxorubicin as first line chemotherapy in advanced breast cancer (ABC). A prospective randomized phase II study with crossover

1995 ◽  
Vol 31 ◽  
pp. S75 ◽  
Author(s):  
R. Paridaens ◽  
P. Bruning ◽  
F. Calabresi ◽  
A. Awada ◽  
J.A. Roy ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Advanced Breast ◽  
First Line ◽  
Randomized Phase Ii ◽  
Line Chemotherapy

Anastrozole Versus Tamoxifen as First-Line Therapy in Postmenopausal Patients With Hormone-Dependent Advanced Breast Cancer

2003 ◽  
Vol 26 (3) ◽  
pp. 317-322 ◽  
Author(s):  
Alfredo Milla-Santos ◽  
Lidon Milla ◽  
Jordi Portella ◽  
Lidon Rallo ◽  
Maria Pons ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

scholarly journals A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study

Oncotarget ◽  
2017 ◽  
Vol 8 (42) ◽  
pp. 73144-73153 ◽  
Author(s):  
Alberto Ocana ◽  
Marta Gil-Martin ◽  
Miguel Martín ◽  
Federico Rojo ◽  
Silvia Antolín ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Phase I ◽  
Advanced Breast Cancer ◽  
Phase I Study ◽  
Kinase Inhibitor ◽  
Src Kinase ◽  
Advanced Breast ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy
Sign in / Sign up

Export Citation Format

Share Document